Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised

TALPHERA, INC.

2025-Q1 EPS reported -$0.16

Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.
Cash and investments $18.6M as of March 31, 2024.
NEPHRO CRRT study enrollment delayed; top-line data guidance (by Sept 30) to be revised.
Dr. Shakil Aslam appointed Chief Development Officer effective May 20, 2024.
Combined R&D and SG&A expenses decreased to $4.2M from $5.3M year-over-year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TALPHERA, INC. reported the three months ended March 31, 2024 results: net income $4.0 million, EPS $0.16 per basic and diluted share.

Period: the three months ended March 31, 2024
Net income: $4.0 million
EPS: $0.16 per basic and diluted share
Result: reported results

Exact text from the filing

Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-016626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.